The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study

2013 ◽  
Vol 92 (6) ◽  
pp. 817-824 ◽  
Author(s):  
Seung-Hwan Shin ◽  
Jae-Ho Yoon ◽  
Seung-Ah Yahng ◽  
Sung-Eun Lee ◽  
Byung-Sik Cho ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Adult Patients ◽  
Severe Aplastic Anemia ◽  
Line Treatment ◽  
Single Center ◽  
First Line ◽  
Rabbit Antithymocyte Globulin ◽  
First Line Treatment

Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study

2016 ◽  
Vol 104 (4) ◽  
pp. 454-461 ◽  
Author(s):  
Suporn Chuncharunee ◽  
Raymond Wong ◽  
Ponlapat Rojnuckarin ◽  
Cheng-Shyong Chang ◽  
Kian Meng Chang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Severe Aplastic Anemia ◽  
Line Treatment ◽  
First Line ◽  
Rabbit Antithymocyte Globulin ◽  
First Line Treatment

Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia

2017 ◽  
Vol 96 (11) ◽  
pp. 1907-1914 ◽  
Author(s):  
Elias H. Atta ◽  
Carlos B. L. Lima ◽  
Danielle S. P. Dias ◽  
Diego V. Clé ◽  
Mariana M. Bonduel ◽  
...  
Keyword(s):  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Early Mortality ◽  
Severe Aplastic Anemia ◽  
Line Treatment ◽  
First Line ◽  
Rabbit Antithymocyte Globulin ◽  
First Line Treatment

Efficacy of antithymocyte globulin as first-line treatment for aplastic anemia—a single-center experience

2017 ◽  
Vol 97 (4) ◽  
pp. 727-730
Author(s):  
I. A. van Zeventer ◽  
J. W. G. M. Schreurs ◽  
E. van den Berg ◽  
A. B. Mulder ◽  
E. Vellenga ◽  
...  
Keyword(s):  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Line Treatment ◽  
Single Center ◽  
First Line ◽  
Single Center Experience ◽  
First Line Treatment

scholarly journals Treatment of aplastic anemia with rabbit antithymocyte globulin as first-line immunosuppressive therapy: A single-center retrospective study

2014 ◽  
Vol 17 (2) ◽  
pp. 57-66
Author(s):  
Yoshimasa Kamoda ◽  
Kiyotaka Izumi ◽  
Futoshi Iioka ◽  
Yoshitomo Maesako ◽  
Takashi Akasaka ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Aplastic Anemia ◽  
Immunosuppressive Therapy ◽  
Antithymocyte Globulin ◽  
Single Center ◽  
First Line ◽  
Rabbit Antithymocyte Globulin

scholarly journals Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment

2018 ◽  
Vol 2 (15) ◽  
pp. 2020-2028 ◽  
Author(s):  
George E. Georges ◽  
Kris Doney ◽  
Rainer Storb
Keyword(s):  
Bone Marrow ◽  
Aplastic Anemia ◽  
Marrow Transplantation ◽  
Severe Aplastic Anemia ◽  
Unrelated Donor ◽  
Line Treatment ◽  
First Line ◽  
Matched Unrelated Donor ◽  
First Line Treatment

Abstract Treatment of severe aplastic anemia has improved significantly over the past 4 decades. This review will summarize the key areas of progress in the use of allogeneic hematopoietic cell transplantation and nontransplant immunosuppressive therapy (IST) for the treatment of aplastic anemia and then summarize the recommendations for first-line treatment. Based on recent data, we argue that guidelines for the initial treatment of patients with newly diagnosed severe aplastic anemia require revision. At the time of diagnosis, before beginning treatment, HLA typing should be done to identify a marrow donor among family members or in the unrelated donor registries, and a marrow transplant should be considered first-line therapy. The priority order of donor source for bone marrow transplantation is: (1) HLA-identical sibling, (2) HLA-matched unrelated donor, and (3) HLA-haploidentical donor if an HLA-matched unrelated donor is not rapidly available. Each of these donor marrow sources may be preferable to nontransplant IST. We make this recommendation because of the long-term persistent risk for disease relapse and secondary myelodysplastic syndrome or acute myeloid leukemia with the use of nontransplant IST for patients with aplastic anemia. In contrast, marrow transplantation is associated with high cure rates of aplastic anemia and a relatively low risk for graft-versus-host disease, with many patients now living for decades without the risk for disease recurrence or the development of clonal disorders. Implementation of this first-line treatment strategy will provide patients with severe aplastic anemia the best chance of long-term disease-free survival.

Sign in / Sign up

Export Citation Format

Share Document